Clinical Trial Update: Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Envafolimab in combination with Axitinib as first-line therapy for advanced renal cell carcinoma; the study status is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Envafolimab (envafolimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Advanced Renal Cell Carcinoma (aRCC) | Phase 2 | Status: NOT_YET_RECRUITING